glp 1 for mash Beyond glucagon-like peptide-1: The promise of polyagonists in metabolic dysfunction–associated steatotic liver disease and metabolic dysfunction–associated steatohepatitis—A systematic review of randomized trials Your Guide to Starting a

Metabolic Control

Provides Antioxidant Support : L-Carnosine acts as a cellular protector, supporting the body's natural antioxidant defenses and helping maintain healthy oxidative balance

Merck began trials of the HMG-CoA reductase inhibitor lovastatin in 1980, and won a historic approval in 1987-- showing the medication produced robust reductions in LDL levels

Danuglipron made it further to Phase IIb, but Pfizer ended the entire program in April 2025 after a single asymptomatic case of potential drug-induced liver injury and dropped its third oral candidate a few months later

In both patient populations with pre-existing cardiovascular disease, DPP-4 inhibitors are recommended as one possible third-line therapy besides SGLT-2 inhibitors, thiazolidinediones, or insulin, when therapeutic goals are not met with the previous dual combination